Company Overview and News
Stop missing out on important events!
REDWOOD CITY, Calif. and MECHELEN, Belgium, Sept. 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced an exclusive agreement to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Score® test on Biocartis' Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.
Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla™ Platform
23andme, Abbott Molecular, Biocartis, Quest Diagnostics, Illumina and Luminex Expected to Exploit Favorable Government Regulations